No Surprise: Genentech Urges Shareholders Not To Tender Shares
This article was originally published in The Pink Sheet Daily
Executive Summary
New details from Genentech’s SEC filing show the two companies have been at an impasse regarding the biotech’s valuation since fall 2008.